09.12.2009 • Topics

Sanofi Spending €350 Million on Vaccine Site

France's Sanofi-Aventis is spending €350 million to build a site to produce a potential blockbuster dengue vaccine that is still in development. The high-technology site should be up and running in 2013 to produce 100 million doses of the dengue vaccine which should become available in 2014 in the endemic regions such as Asia Pacific. The new plant will be located in Neuville-sur-Saone, near Sanofi Pasteur's headquarters in Lyon, France. Sanofi has 12 manufacturing sites under construction or undergoing major renovation and they will come on line in 2009. Among them is the recently approved U.S. factory in Pennsylvania, which is to produce the seasonal flu vaccine Fluzone.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read

Photo
14.05.2025 • Topics • Pharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • Topics • Strategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.